BridgeBio Oncology Therapeutics (BBOT) Total Liabilities (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Total Liabilities of $45.4 million for Q1 2026, up 21.67% sequentially from $37.3 million in Q4 2025, and up 513.82% YoY from $7.4 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Total Liabilities (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Total Liabilities for 4 years, with the latest figure at $45.4 million in Q1 2026.
- Quarterly Total Liabilities rose 513.82% year-over-year to $45.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.4 million (up 513.82% YoY) and the FY2025 annual result came in at $37.3 million, up 90.42% from the prior year.
- Total Liabilities improved to $45.4 million in Q1 2026 per BBOT's latest filing, from $37.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $45.4 million in Q1 2026 and troughed at $396463.0 in Q4 2023.
- A 4-year average of $17.3 million and a median of $7.8 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 4838.67% in 2024, then jumped 33.33% in 2025.
- Over 4 years, Total Liabilities stood at $396463.0 in 2023, then jumped by 4838.67% to $19.6 million in 2024, then soared by 90.42% to $37.3 million in 2025, then grew by 21.67% to $45.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $45.4 million, $37.3 million, and $38.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 53.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.59 Mn |
| Mar 31, 2026 | 45.37 Mn |
| Dec 31, 2025 | 37.29 Mn |
| Sep 30, 2025 | 38.09 Mn |
| Jun 30, 2025 | 8.15 Mn |
| Mar 31, 2025 | 7.39 Mn |
| Dec 31, 2024 | 19.58 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 5.60 Mn |
| Mar 31, 2024 | 5.54 Mn |
| Dec 31, 2023 | 396,463.00 |